Trachoma Clinical Trial
Official title:
Cost-effectiveness of Three Alternative Azithromycin Treatment Strategies for Trachoma Control in Tanzania
After single, yearly, mass treatment of communities with azithromycin for active trachoma, what is the added effectiveness for reduction of trachoma and ocular C. trachomatis infection at one, two, and three years, relative to the added costs, of community-based surveillance and treatment of cases of severe trachoma (TI) semi-annually or every 4 months?
An important component of a trachoma control program is the effective use of antibiotics,
particularly azithromycin, to reduce the pool of chlamydial ocular infection in the
communities. A reduction in the pool of infection will reduce the likelihood of transmission
and, coupled with effective hygiene and environmental changes, theoretically lead to
reduction in disease to the point where active trachoma is no longer a public health
problem. Our previous experience with the use of azithromycin for community treatment has
shown that even with high rates of coverage, hyperendemic communities will start to
experience re-emergent trachoma following treatment by one year. Therefore, it is urgent to
determine if there is another treatment strategy for these villages to keep the pool of
infection low, and eventually eliminated.A combination approach consisting of mass treatment
at yearly intervals and surveillance with a targeted treatment approach in the interim
period may be effective in maintaining the low rate of re-emergent disease.We propose to
test the cost-effectiveness of three alternative strategies for the frequency of provision
of azithromycin, in the context of the Tanzanian National Trachoma Control Program. The
strategies have been developed to build on the epidemiological knowledge of trachoma in this
area, to be locally appropriate in terms of feasibility and personnel, and to be consistent
with the goal of enhancing community control of the program.
A total of nine villages in the Kongwa district of Tanzania will be randomized to one of
three groups (a total of three villages per group). The nine villages, with active trachoma
rates in pre-school children of 50% or greater, would be slated for enrollment in the
National Program, but not currently receiving treatment. Surveys for active trachoma status
would be carried out in 300 randomly selected, children ages 1-7 years (pre-school)in each
village at baseline, at 6 months post mass treatment, and at one, two, and three years post
baseline. The following treatment strategies will be used:
Control villages: Usual practice: The three villages randomized to this arm would receive
mass treatment of the community once a year as part of the Tanzania National Trachoma
Control program.
Intervention 1. Usual practice plus community surveillance for TI cases and treatment at 6
months: The three villages randomized to this arm would receive mass treatment, similar to
the usual practice arm, but in addition, would have a cadre of community volunteers, trained
to recognize TI. They will screen their neighborhoods, examining all pre-school children and
mothers, and arrange with the health worker for another round of treatment for TI cases and
their families at 6 months, and 18 months post baseline.
Intervention 2: Usual practice plus community surveillance for TI cases and treatment every
4 months: The three villages randomized to this arm would have an approach identical to
intervention 1, but with surveillance and treatment of TI cases at 4 and 8 months instead of
at 6 months.For the second year, they would have surveillance and treatment at 6 months.
Cost data on the community surveillance and treatment program will be collected throughout
the first year. Analyses will focus on the additional benefit on reduction in prevalence of
trachoma, and ocular C. trachomatis infection, at one, two, and three years of the two
alternative strategies, relative to yearly mass treatment alone, and the cost-effectiveness
of the three strategies.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03676140 -
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 3 | |
Completed |
NCT01949454 -
Fluorometholone as Ancillary Therapy for TT Surgery
|
N/A | |
Completed |
NCT01202331 -
Tripartite International Research for the Elimination of Trachoma
|
Phase 4 | |
Completed |
NCT05634759 -
Enhancing the A in SAFE for Trachoma
|
Phase 4 | |
Recruiting |
NCT04185402 -
Azithromycin Reduction to Reach Elimination of Trachoma
|
Phase 4 | |
Active, not recruiting |
NCT00886015 -
Modified Instrumentation for Surgery to Correct Trichiasis
|
Phase 3 | |
Completed |
NCT00792922 -
Partnership for Rapid Elimination of Trachoma
|
Phase 4 | |
Completed |
NCT00522860 -
A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery
|
Phase 4 | |
Completed |
NCT00221364 -
Trachoma Elimination Follow-up
|
Phase 4 | |
Completed |
NCT00322972 -
Trachoma Amelioration in Northern Amhara (TANA)
|
Phase 4 | |
Withdrawn |
NCT00286026 -
Azithromycin in Control of Trachoma II
|
Phase 4 | |
Completed |
NCT00347763 -
Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
|
Phase 4 | |
Terminated |
NCT03997487 -
Smartphone App for Taking Images of Conjunctivae
|
N/A | |
Terminated |
NCT04002726 -
App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders
|
N/A | |
Not yet recruiting |
NCT06289647 -
Azithromycin Reduction to Reach Elimination of Trachoma B
|
Phase 4 | |
Withdrawn |
NCT02655432 -
Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
|
Phase 0 | |
Completed |
NCT01767506 -
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
|
N/A | |
Completed |
NCT00618449 -
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
|
Phase 4 | |
Completed |
NCT00356720 -
Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma
|
Phase 3 | |
Completed |
NCT03813069 -
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
|
Phase 2 |